Editas medicine stock price.
Editas Medicine closed an underwritten offering of 4,025,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses. This included 525,000 shares issued upon exercise in full by the underwriters of their option to purchase additional shares.
Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. Editas Medicine Inc (NASDAQ: EDIT) has agreed to license its proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies to Shoreline Biosciences.Price as of December 1, 2023, 4:00 p.m. ET ... This fact has led to a stomach-churning level of volatility among stocks tied to CRISPR and related forms of gene ... Editas …The stock bounced back a bit toward the end of the day but was still down as much as 13.8% by 2 p.m. EST. Editas has a 52-week low of $9.59 and a 52-week high of $37.50, and is down more than 60% ...
In the last 3 months, 6 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $14.67 with a high of $22.00 and a low of $8.00.CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by …On average, Wall Street analysts predict. that Editas Medicine's share price could reach $14.00 by Oct 24, 2024. The average Editas Medicine stock price prediction forecasts a potential upside of 31.95% from the current EDIT share price of $10.61 .
Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Robinhood (HOOD 5.91%), in particular, makes this process a breeze with its stock slices option (useful for weighting) and commission-free trading. Put simply, you …
With Editas Medicine stock trading at $10.49 per share, the total value of Editas Medicine stock (market capitalization) is $856.76M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016.View the real-time EDIT price chart on Robinhood, Editas Medicine stock live quote and latest news. You can buy and sell Editas Medicine (EDIT) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news.Editas Medicine (EDIT) stock price prediction is 21.694681385149 USD. The Editas Medicine stock forecast is 21.694681385149 USD for 2024 November 30, ...Get the LIVE share price of Editas Medicine Inc(EDIT) and stock performance in one place to strengthen your trading strategy in US stocks. Now Start Investing in Editas Medicine Inc on Groww. Editas Medicine Inc. Healthcare. $10.77 +0.24(2.28%) 1D. 1D. 1W. 1M. 1Y. 3Y. 5Y. Performance. Open Price: Prev. Close: Volume: Avg. Volume: …Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...
CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.
You may have come across Amox Clav when visiting a doctor with the symptoms of an infection. Amox Clav is a combination medicine that may be used to treat a wide variety of infections.
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. By Alex Carchidi – Oct 2, 2023 at 10:00AM ... Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET.In the last 3 months, 18 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $19.17 with a high of $43.00 and a low of $6.00.Editas Medicine Stock Forecast and Price Target. Based on the current earnings figures, this year's price targets for Editas Medicine were recently set by distinguished experts, with an average mark of $12.00. If it reached this goal, it would represent a potential upside of approximately 11.42% from the previous closing price in December, 2023.Get a real-time Editas Medicine, Inc. (EDIT) stock price quote with breaking news, financials, statistics, charts and more.Conference Call. The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the third quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas …Apr 3, 2023 · Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...
Summary of all time highs, changes and price drops for Editas Medicine; Historical stock prices; Current Share Price: US$10.77: 52 Week High: US$11.93: 52 Week Low ...Select an options expiration date from the drop-down list at the top of the table, and select "Near-the-Money" or "Show All' to view all options. Note: Option ...Consider, for instance, Editas Medicine (EDIT-6.20%) ... Stock Advisor list price is $199 per year. Join Stock Advisor Cumulative Growth of a $10,000 Investment in Stock Advisor.Editas Medicine (EDIT) Stock Price Performance. Editas Medicine (EDIT) Stock Key Data. ... Consensus Price Target is the stock price analysts expect to see within a …Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.
The Editas Medicine, Inc stock price fell by -0.754% on the last day (Thursday, 30th Nov 2023) from $10.61 to $10.53. During the last trading day the stock fluctuated 5.51% from a day low at $10.44 to a day high of $11.01. The price has risen in 6 of the last 10 days and is up by 19.12% over the past 2 weeks.
Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progress in developing a gene-editing therapy ...Phil Nadeau’s Buy rating for Editas Medicine’s stock is premised on a variety of factors. Key among these is the company’s strong financial position, with reported cash reserves of $446 ...Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions. CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ...Consider, for instance, Editas Medicine (EDIT-6.20%) ... Stock Advisor list price is $199 per year. Join Stock Advisor Cumulative Growth of a $10,000 Investment in Stock Advisor.Nov 20, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 62.28% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $11.14 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ... With Editas Medicine stock trading at $6.26 per share, the total value of Editas Medicine stock (market capitalization) is $511.02M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016.
Over the past year, shares of gene-editing companies Editas Medicine ( EDIT -0.23%) and CRISPR Therapeutics ( CRSP 6.42%) have shot up 129% and 212%, respectively. Their mouth-watering returns ...
11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 46.41% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $9.83 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ...Editas Medicine stock price prediction is an act of determining the future value of Editas Medicine shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Editas Medicine's future price could yield a significant profit.Nov 2, 2023 · Editas Medicine releases earnings for the most recent quarter on November 3. Analysts predict Editas Medicine will release losses per share of $0.575. Go here to track Editas Medicine stock price ... Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.Editas Medicine has granted the underwriters a 30-day op ... today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 ...Recent reports have lowered Editas Medicine’s price target from $36.00 to $30.00 and raised it from $13.00 to $15.00. Editas Medicine’s stock opened at $6.71 and has a 50-day moving average of $8.70 and a 200-day moving average of $9.86. The company’s market capitalization is $462.79 million, and it has a PE ratio of -2.09 and a …Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 21, 2023 · Editas Medicine stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for Editas Medicine analysts is $ 13.53 . Today 200 Day Moving Average is the resistance level ( 8.45 $).
Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis. Feb 17, 2021 · Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET ... Editas Medicine (EDIT 2.28%) is on the cutting edge of CRISPR. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR ... Nonetheless, the filing did say that Editas already raised $163.3 million from selling preferred stock to private investors like Bill Gates and Google Ventures, along with other backers like Sun ...In the last 3 months, 6 analysts have offered 12-month price targets for Editas Medicine. The company has an average price target of $14.67 with a high of $22.00 and a low of $8.00.Instagram:https://instagram. buy traction uranium stockhow to use ameritradediscover financial newsreit etf monthly dividend Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Nov 24, 2023 · Get a real-time Editas Medicine, Inc. (EDIT) stock price quote with breaking news, financials, statistics, charts and more. stryker corp share priceinvestorsobservers Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. By Alex Carchidi – Oct 2, 2023 at 10:00AM ... Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET.Dec 1, 2023 · 12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price. nyse wpm What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ...With all that said, here are the most exciting genomic stocks that you won’t want to miss out on. NTLA Intellia Therapeutics $37.75 BEAM Beam Therapeutics $30.71 EDIT Editas Medicine $8.16.Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ...